AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30239842
Drug: Intravaginal testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal testosterone (IVT) cream
Trial: 27696203
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) 45 mg/m2 (days 6-8); 15 mg/m2 (days 9-21)
Trial: 25102884
Drug: Compound Borax
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Borax Solution
Trial: 19155235
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous cyclophosphamide (LD IVCY) followed by azathioprine (AZA)
Trial: 19155235
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous cyclophosphamide (HD IVCY) followed by azathioprine (AZA)
Trial: 15699223
Drug: High-calorie complex
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calorie complex carbohydrate (HC-CC) meal
Trial: 15699223
Drug: All meals
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All meals (HC-SC, HC-CC, LC)
Trial: 15699223
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and Leptin
Trial: 12854476
Drug: PGE1 infusion
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE1 infusion at a rate of 0.01 microgram.kg‐1.min‐1 during and after the operation (60‐80 hrs)
Trial: 8605674
Drug: Cancer antigen
RxNorm normalized name: Cancer antigen 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen assessment during therapy
Trial: 31111049
Drug: HPVADL18® (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPVADL18® (200 mg Echinacea Purpurea and Echinacea Angustifolia) for 4 months after laser therapy
Trial: 31111049
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy (Control Group B)
Trial: 26120407
Drug: Oxytocin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (50 units in 500 cc normal saline, increased to maximum 300 units) with laminaria (6 hours)
Trial: 21205237
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator (3-6 h after symptom onset)
Trial: 21205237
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator (3-4.5 h after symptom onset)
Trial: 21205237
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator (4.5-6 h after symptom onset)
Trial: 21205237
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator
Trial: 16426264
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg subcutaneous sumatriptan (early administration)
Trial: 16426264
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg subcutaneous sumatriptan (late administration)
Trial: 11296099
Drug: Continuation-phase cognitive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation-phase cognitive therapy (C‐CT) for 8 months (10 sessions)
Trial: 8500499
Drug: Oxyprogesterone caproate
RxNorm normalized name: Hydroxyprogesterone Caproate
DrugBank: Hydroxyprogesterone caproate (DB06789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxyprogesterone caproate (OPC) administered preoperatively and after surgical and combined therapy for 6 to 36 months
Trial: 8500499
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Oxyprogesterone caproate (OPC) and Tamoxifen administered additionally to surgical and combined therapy
Trial: 8500499
Drug: Adjuvant hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormone therapy in endometrial carcinoma patients
Trial: 3566252
Drug: Cefoperazone and
RxNorm normalized name: Cefoperazone and sulbactam only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone and tobramycin in combination
Trial: 18253066
Drug: A. vera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A. vera gel (97.5%)
Trial: 18253066
Drug: 1% hydrocortisone
RxNorm normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1% hydrocortisone in placebo gel
Trial: 15986873
Drug: pegIFNalpha‐2a (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegIFNalpha‐2a (180 microg/week) plus ribavirin (800 mg/day)
Trial: 8696717
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m2, escalated by 250 mg/m2/week to 1750 mg/m2) and Cisplatin (25 mg/m2 escalated to 30 mg/m2) administered as 30 min infusions weekly x 3 with a week of rest.
Trial: 6133802
Drug: Azatadine maleate/pseudoephedrine
RxNorm normalized name: Azatadine Maleate/Pseudoephedrine Sulfate 1 MG-120 MG Oral Tablet, Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azatadine maleate/pseudoephedrine sulfate syrup
Trial: 25498742
Drug: Abdominal massage
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal massage administered twice daily for 15 minutes
Trial: 23323626
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic injection (bupivacaine) during banding
Trial: 23323626
Drug: No local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No local anaesthetic injection (control)
Trial: 20821330
Drug: 5-FU (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (400 mg/m2 bolus, 600 mg/m2 22 h continuous infusion day 1 and 2) + cisplatin (50 mg/m2 day 1) + pegylated liposomal doxorubicin (20 mg/m2 day 1 every two weeks)
Trial: 20821330
Drug: 5-FU (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (400 mg/m2 bolus, 600 mg/m2 22 h continuous infusion day 1 and 2) + cisplatin (50 mg/m2 day 1) + mitomycin-C (7 mg/m2 every 6 weeks)
Trial: 20006142
Drug: A/Vietnam/1194/2004 A/H5N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/Vietnam/1194/2004 A/H5N1 vaccine (5microg, 15microg or 45microg) with a 50microg LT adjuvant patch applied over the injection site
Trial: 20006142
Drug: Two-injection/two-patch 45microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-injection/two-patch 45microg HA regimen
Trial: 20006142
Drug: A/Vietnam/1194/2004 A/H5N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/Vietnam/1194/2004 A/H5N1 vaccine (45microg) with LT patch on second immunization
Trial: 20006142
Drug: A/Vietnam/1194/2004 A/H5N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/Vietnam/1194/2004 A/H5N1 vaccine (45microg) without LT patch
Trial: 10547405
Drug: Osteopathic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manual therapy
Trial: 8690821
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of torsemide (75 mg over 24 hours with a 25 mg loading bolus)
Trial: 8690821
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of torsemide (100 mg)
Trial: 2062989
Drug: Midazolam (6.13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (6.13 mg)
Trial: 2062989
Drug: Diazepam (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (6.4 mg)
Trial: 31996543
Drug: Norepinephrine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (8 μg bolus)
Trial: 31996543
Drug: Phenylephrine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (100 μg bolus)
Trial: 16388091
Drug: Troglitazone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (600 mg/d)
Trial: 12161056
Drug: Repaglinide (n=116,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (n=116, preprandially three-times daily)
Trial: 12161056
Drug: Glibenclamide (n=119,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (n=119, preprandially once- or twice-daily)
Trial: 2194053
Drug: 7.5mg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5mg of dibucaine with 0.05mg of buprenorphine (G-II)
Trial: 2194053
Drug: 7.5mg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5mg of dibucaine with 0.25mg of morphine (G-III)
Trial: 2194053
Drug: 7.5mg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5mg of dibucaine with 0.25mg of morphine and 0.2mg of naloxone (G-IV)
Trial: 2194053
Drug: 7.5mg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5mg of dibucaine only (G-I)
Trial: 348378
Drug: Para-aminosalicylic acid
RxNorm normalized name: Para-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks
Trial: 348378
Drug: Para-aminosalicylic acid
RxNorm normalized name: Para-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks in hypercholesterolemic patients
Trial: 348378
Drug: Para-aminosalicylic acid
RxNorm normalized name: Para-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks in hypertriglyceridemia type IV patients
Trial: 31927569
Drug: Cognitive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive and behavioral therapy for insomnia (CBTi) over 4 weeks (n=72)
Trial: 31927569
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control (n=73)
Trial: 25771069
Drug: Enalapril and
RxNorm normalized name: enalapril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril and folic acid (10 mg enalapril, 0.8 mg folic acid)
Trial: 25771069
Drug: Enalapril alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril alone (10 mg)
Trial: 23585557
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality (VR) exposure therapy, n = 7
Trial: 23585557
Drug: Imaginal Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaginal Exposure (IE) therapy, n = 8
Trial: 18795264
Drug: Naltrexone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone treatment with cognitive behavioral therapy
Trial: 1694236
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine and daunorubicin (course one) followed by standard-dose cytarabine and daunorubicin (course two)
Trial: 1694236
Drug: Azacitidine and
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine and doxorubicin (course one) followed by standard-dose cytarabine, daunorubicin, and thioguanine (course two)
Trial: 1694236
Drug: High-dose cytarabine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine-based chemotherapy and/or allogeneic bone marrow transplantation (BMT)
Trial: 1694236
Drug: ALP3 postremission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALP3 postremission chemotherapy regimen
Trial: 619938
Drug: Glycopyrronium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium 0.2 mg intramuscularly
Trial: 619938
Drug: Glycopyrronium (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium (oral route)
Trial: 619938
Drug: Glycopyrronium (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium (intravenous route)
Trial: 619938
Drug: Glycopyrronium (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium (intramuscular route)
Trial: 619938
Drug: Larger doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger doses of Glycopyrronium
Trial: 29468701
Drug: 50 mg/d
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/d allopurinol
Trial: 29468701
Drug: 100 mg/d
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/d allopurinol
Trial: 24418037
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (n = 50)
Trial: 20497967
Drug: Matuzumab plus
RxNorm normalized name: Matuzumab
DrugBank: Matuzumab (DB05101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matuzumab plus ECX (800 mg matuzumab weekly, epirubicin 50 mg/m², cisplatin 60 mg/m², capecitabine 1250 mg/m²)
Trial: 20497967
Drug: ECX alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECX alone (epirubicin 50 mg/m², cisplatin 60 mg/m², capecitabine 1250 mg/m²)
Trial: 18456138
Drug: Implant group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant group
Trial: 12448067
Drug: Atenolol (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (n = 28; dose 25 to 100 mg)
Trial: 12448067
Drug: Terazosin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (n = 26; dose 1 to 10 mg)
Trial: 9607387
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 to 10 mg once daily (n = 55)
Trial: 9607387
Drug: Nifedipine SR
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine SR 20 mg twice daily (n = 48)
Trial: 7883543
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg enoxaparin administered 12 hours before surgery
Trial: 7883543
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 12 hours before surgery
Trial: 2244403
Drug: Flurbiprofen 50
RxNorm normalized name: flurbiprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 50 mg tid
Trial: 402206
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment methods (inguinal orchiectomy with irradiation and pre- and postoperative irradiation with lymphadenectomy)
Trial: 28467880
Drug: Teprotumumab (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprotumumab (administered intravenously once every 3 weeks for a total of eight infusions)
Trial: 28467880
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered intravenously once every 3 weeks for a total of eight infusions)
Trial: 22805083
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine group (CMG) - treated with Chinese medicine according to syndrome differentiation for 48 weeks.
Trial: 22805083
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (WMG) - treated with donepezil at a dose of 5 mg once daily for 48 weeks.
Trial: 19910654
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (2.4 g/d; 2,000 mg EPA, 400 mg DHA)
Trial: 31018727
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) using PICO, Smith & Nephew, St. Petersburg, FL
Trial: 31018727
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) using PICO, Smith & Nephew, St. Petersburg, FL (after matching)
Trial: 30064450
Drug: Betaine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine (2.5 g/day)
Trial: 26937942
Drug: N2O (nitrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N2O (nitrous oxide) inhalation
Trial: 23345635
Drug: Rivastigmine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (up to 12 mg/day for 20 weeks)
Trial: 19707287
Drug: Anticoagulant and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant and antiplatelet agents (specific agents not detailed)
Trial: 15566681
Drug: EMBE and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMBE and after-loading treatment
Trial: 8322572
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg.kg‐1
Trial: 8322572
Drug: Methohexitone 2
RxNorm normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexitone 2 mg.kg‐1
Trial: 8322572
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 and 2.5 mg.kg‐1
Trial: 3709070
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia of the upper airways
Trial: 31566918
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment for childhood insomnia (CBT‐CI)
Trial: 29772190
Drug: Dental implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental implant placement
Trial: 22934396
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (Nifedipine tablets 20 mg orally in the morning)
Trial: 18376092
Drug: Intermittent methylene
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent methylene blue therapy (Gr I, n=5)
Trial: 18376092
Drug: Continuous methylene
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous methylene blue therapy (Gr II, n=6)
Trial: 7024868
Drug: Azatadine maleate
RxNorm normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azatadine maleate (Zadine) 2 mg twice daily
Trial: 7024868
Drug: Azatadine maleate
RxNorm normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azatadine maleate (Zadine) 1 mg twice daily
Trial: 30040589
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (CBT) for sexual dysfunction
Trial: 20860913
Drug: Golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 50 mg every 4 weeks
Trial: 26416942
Drug: Topical and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical and intraurethral 2% lidocaine gel
Trial: 24211510
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg daily) for 28 days
Trial: 22475140
Drug: Telbivudine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine (600 mg/d until postpartum week 4)
Trial: 19881322
Drug: Continuous passive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous passive motion (CPM) started on the first postoperative day with conventional physical therapy (n=29)
Trial: 19881322
Drug: Continuous passive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous passive motion (CPM) started on the third postoperative day with conventional physical therapy (n=29)
Trial: 19881322
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy only (control group, n=28)
Trial: 11343232
Drug: Butyl cyanoacrylate
RxNorm normalized name: N-butyl cyanoacrylate
DrugBank: Enbucrilate (DB12358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butyl cyanoacrylate injection (group A)
Trial: 3297595
Drug: verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 120 mg three times daily
Trial: 28292551
Drug: Continuous paravertebral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous paravertebral block at levels T1 and T2 with bupivacaine infusion
Trial: 23299960
Drug: Nebulised magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised magnesium sulphate (151 mg per dose)
Trial: 17100370
Drug: 0.025 mg/d
RxNorm normalized name: estradiol 0.025 MG/Day Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg/d transdermal estradiol
Trial: 17100370
Drug: 0.05 mg/d
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/d transdermal estradiol